Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A. Balis, William Canovatchel, Gary Meininger

Research output: Contribution to journal › Article › peer-review

663 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science